Spero Therapeutics Q3 EPS $(0.33) Misses $(0.30) Estimate, Sales $2.01M Miss $5.42M Estimate
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.30) by 10 percent. This is a 52.86 percent increase over losses of $(0.70) per share from